Predict your next investment

Venture Capital
bridgescale.com

See what CB Insights has to offer

Investments

35

Portfolio Exits

15

Funds

2

About Bridgescale Partners

Bridgescale Partners is a Silicon Valley-based private equity and venture capital firm that invests in U.S.-based, late-stage, technology-enabled companies. Bridgescale's investment focus includes growth equity in corporate spinouts, venture-backed and bootstrapped companies, middle market private equity investments, and management-led buyouts.

Bridgescale Partners Headquarter Location

2200 Sand Hill Road

Menlo Park, California, 94025,

United States

650-854-6100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Bridgescale Partners News

Chronometriq secures $20M Series B led by Full In Partners

Oct 1, 2019

Chronometriq secures $20M Series B led by Full In Partners In July 2017, Chronométriq raised over $3.5 million in Series A financing led by Bridgescale Partners. Founded in 2012, Montreal based Chronométriq is a leader in digital healthcare management through its suite of products enabling full-cycle appointment management for clinics and patients alike. photo credit: Chronométriq News Release Chronometriq Raises $20 Million in Series B Funding Round to Fuel Growth in the United States and Solidify Leadership Position in Canada MONTREAL, Oct. 1, 2019 /PRNewswire/ – Chronometriq, the Montreal-based provider of access-to-care and patient engagement tools, announced that the company has secured more than $20 million CAD in Series B funding. New York growth investor Full In Partners led the round with additional participation from existing investors. This financing will help further Chronometriq’s leadership position in Canada and give them significant opening traction in the United States. “We are very proud and excited to have attracted Full In as investors and partners in this round. During our process Full In stood out among 200-plus other firms for their compassion, value-add orientation, and long track record of partnering with founders to grow companies like ours” said Yan Raymond-Lalande, Co-Founder and CEO. “We’ve spent the last year in the U.S. optimizing our products and strategy for the market and have entered into an integration and distribution partnership with multiple major U.S. players. Thanks to our efforts and the operational support provided by Full In, we are now poised for successful expansion into the U.S., ” added Remi Richard, Co-Founder and Head of Growth. Elodie Dupuy, Co-Founder and Managing Director at Full In commented “The Chronometriq team has built an exciting suite of solutions that we think have the potential to transform healthcare for doctors and patients across North America. Yan and Remi immediately felt like family to us and ideal partners and we are so excited to be aligned in our pursuit of glory.” About Chronometriq (cMetricHealth, U.S.) Chronometriq, founded in 2012, was named one of the twenty-five most innovative businesses by C2-MTL. The company is a leader in digital healthcare management through its suite of products enabling full-cycle appointment management for clinics and patients alike. In the past year alone, Chronometriq served 12 million users through its network of clinics across North America. To learn more about Chronometriq, please visit: chronometriq.com. About Full In Partners Full In Partners is a new women-led growth equity fund based in New York, founded by Elodie Dupuy, Jess Davis and Eric Tonkyn. The firm is focused on changing the fundraising experience for entrepreneurs through the application of proprietary technology and value-add strategy, guidance, and relationships post-investment. To learn more about Full In, please visit: https://fullinpartners.com/ SOURCE Chronometriq Inc.

Bridgescale Partners Investments

35 Investments

Bridgescale Partners has made 35 investments. Their latest investment was in Finomial as part of their Series B on February 2, 2018.

CBI Logo

Bridgescale Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/22/2018

Series B

Finomial

$7.04M

No

1

12/11/2017

Series B

BitGo

$42.5M

No

9

7/11/2017

Series A

Pomelo Health

$2.7M

Yes

3

2/23/2016

Series A - IV

Subscribe to see more

$99M

Subscribe to see more

10

1/13/2015

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/22/2018

12/11/2017

7/11/2017

2/23/2016

1/13/2015

Round

Series B

Series B

Series A

Series A - IV

Series A - III

Company

Finomial

BitGo

Pomelo Health

Subscribe to see more

Subscribe to see more

Amount

$7.04M

$42.5M

$2.7M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

9

3

10

10

Bridgescale Partners Portfolio Exits

15 Portfolio Exits

Bridgescale Partners has 15 portfolio exits. Their latest portfolio exit was Finomial on October 26, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/26/2021

Acquired

$99M

7

5/5/2021

Acquired

$99M

13

4/20/2021

Acq - Fin

$99M

2

2/23/2017

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

2/3/2016

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/26/2021

5/5/2021

4/20/2021

2/23/2017

2/3/2016

Exit

Acquired

Acquired

Acq - Fin

Acq - Fin

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

7

13

2

10

10

Bridgescale Partners Acquisitions

2 Acquisitions

Bridgescale Partners acquired 2 companies. Their latest acquisition was Incentium on October 23, 2008.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/23/2008

$99M

Acq - Fin

3/10/2008

Subscribe to see more

$99M

Subscribe to see more

0

Date

10/23/2008

3/10/2008

Investment Stage

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Acq - Fin

Subscribe to see more

Sources

0

Bridgescale Partners Fund History

2 Fund Histories

Bridgescale Partners has 2 funds, including Bridgescale Opportunities III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/22/2017

Bridgescale Opportunities III

Diversified Private Equity

Closed

$4.1M

1

12/31/2006

Bridgescale Partners

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/22/2017

12/31/2006

Fund

Bridgescale Opportunities III

Bridgescale Partners

Fund Type

Diversified Private Equity

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$4.1M

$99M

Sources

1

10

Bridgescale Partners Team

2 Team Members

Bridgescale Partners has 2 team members, including former Managing Director, Rob Chaplinsky.

Name

Work History

Title

Status

Matthew T. Cowan

Founder

Current

Rob Chaplinsky

Dryft, Mohr Davidow Ventures, H&Q Life Sciences Investors, and Intel

Managing Director

Former

Name

Matthew T. Cowan

Rob Chaplinsky

Work History

Dryft, Mohr Davidow Ventures, H&Q Life Sciences Investors, and Intel

Title

Founder

Managing Director

Status

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.